Bayer Blames Macroeconomic Pressures For Lower Volumes In Q1
Inflationary pressures and supply constraints led to volume declines at Bayer Consumer Health in Q1. However, price rises offset these headwinds helping the business to post a 4% rise in sales.
You may also be interested in...
Major Europe-based consumer health players Reckitt, Haleon, Sanofi and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q1 2023 results over the coming weeks.
Activist investors are pushing for a break-up of Bayer's conglomerate structure and the sale of its Consumer Health division. It will be up to incoming CEO Bill Anderson to make the call.
CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.